UNLABELLED: Tolerogenic DCs (tolDCs) are being researched as a promising intervention strategy also in autoimmune diseases including type 1 diabetes (T1D). T1D is a T-cell-mediated, organ-specific disease with several well-defined and rather specific autoantigens, i.e., proinsulin, insulin, glutamic acid decarboxylase 65 (GAD65), that have been used in animal as well as human intervention trials in attempts to achieve a more efficient, specific immunotherapy. In this study, we have tested tolerogenic DCs for their effectiveness to prevent adoptive transfer of diabetes by diabetogenic splenocytes into non-obese diabetes (NOD)-severe combined immunodeficiency (NOD-SCID) recipients. While i.p. application of tolDCs prepared from bone marrow of prediabetic NOD mice by vitamin D2 and dexamethasone significantly reduced diabetes transfer into the NOD-SCID females, this effect was completely abolished when tolDCs were loaded with the mouse recombinant GAD65, but also with a control protein-ovalbumin (OVA). The effect was not dependent on the presence of serum in the tolDC culture. Similar results were observed in NOD mice. Removal of possible bystander antigen-presenting cells within the diabetogenic splenocytes by negative magnetic sorting of T cells did not alter this surprising effect. Tolerogenic DCs loaded with an immunodominant mouse GAD65 peptide also displayed diminished diabetes-preventive effect. Tolerogenic DCs were characterized by surface maturation markers (CD40, CD80, CD86, MHC II) and the lipopolysaccharide stability test. Data from alloreactive T cell proliferation and cytokine induction assays (IFN-γ) did not reveal the differences observed in the diabetes incidence. Migration of tolDCs, tolDCs-GAD65 and tolDCs-OVA to spleen, mesenteric- and pancreatic lymph nodes displayed similar, mucosal pattern with highest accumulation in pancreatic lymph nodes present up to 9 days after the i.p. APPLICATION: These data document that mechanisms by which tolDCs operate in vivo require much better understanding for improving efficacy of this promising cell therapy, especially in the presence of an antigen, e.g., GAD65.

Department of Immunology 2nd Medical School Charles University Prague Czechia

Institute of Microbiology of the Czech Academy of Sciences v v i Nový Hrádek Czechia

Institute of Microbiology of the Czech Academy of Sciences v v i Prague Czechia

SOTIO a s Prague Czechia

See more in PubMed

Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev (1994) 15:516–42.10.1210/edrv-15-4-516 PubMed DOI

Harrison LC, Colman PG, Honeyman MC, Kay TWH. Type 1 diabetes – from pathogenesis to prevention. In: Turtle JR, Kaneko T, Osata S, editors. Diabetes in the New Millennium. Sydney, Australia: Pot Still Press; (1999). p. 85–100.

Van Belle TL, Taylor P, von Herrath MG. Mouse models for type 1 diabetes. Drug Discov Today Dis Models (2009) 6:41–5.10.1016/j.ddmod.2009.03.008 PubMed DOI PMC

Mukherjee G, Dilorenzo TP. The immunotherapeutic potential of dendritic cells in type 1 diabetes. Clin Exp Immunol (2010) 161:197–207.10.1111/j.1365-2249.2010.04157.x PubMed DOI PMC

Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol (2002) 32:2021–30.10.1002/1521-4141(200207)32:7<2021::AID-IMMU2021>3.0.CO;2-J PubMed DOI

Giannoukakis N, Trucco M. A role for tolerogenic dendritic cell-induced B-regulatory cells in type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes (2012) 19:279–87.10.1097/MED.0b013e328355461b PubMed DOI

Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest (1992) 90:741–8.10.1172/JCI115946 PubMed DOI PMC

Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol (2004) 173:4331–41.10.4049/jimmunol.173.7.4331 PubMed DOI

Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes (1999) 48:2300–8.10.2337/diabetes.48.12.2300 PubMed DOI

Hayashi T, Yao S, Crain B, Promessi VJ, Shyu L, Sheng C, et al. Induction of tolerogenic dendritic cells by a PEGylated TLR7 ligand for treatment of type 1 diabetes. PLoS One (2015) 10:e0129867.10.1371/journal.pone.0129867 PubMed DOI PMC

Haase C, Yu L, Eisenbarth G, Markholst H. Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin Exp Immunol (2010) 160:331–9.10.1111/j.1365-2249.2010.04104.x PubMed DOI PMC

Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, et al. IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice. Clin Immunol (2011) 139:336–49.10.1016/j.clim.2011.03.003 PubMed DOI

Marin-Gallen S, Clemente-Casares X, Planas R, Pujol-Autonell I, Carrascal J, Carrillo J, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol (2010) 160:207–14.10.1111/j.1365-2249.2009.04082.x PubMed DOI PMC

Pujol-Autonell I, Ampudia RM, Monge P, Lucas AM, Carrascal J, Verdaguer J, et al. Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice. ISRN Endocrinol (2013) 2013:346987.10.1155/2013/346987 PubMed DOI PMC

Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, et al. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol (2008) 127:176–87.10.1016/j.clim.2007.12.009 PubMed DOI PMC

Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 34:2026–32.10.2337/dc11-0472 PubMed DOI PMC

Giannoukakis N. Tolerogenic dendritic cells for type 1 diabetes. Immunotherapy (2013) 5:569–71.10.2217/imt.13.50 PubMed DOI

Roep B. Immune Intervention with Tolerogenic Dendritic Cells in Type 1 Diabetes. A Phase 1 Safety Study Called D-Sense Netherland Trial Info (2015), Clinical Trial No.: NTR5542. Available from: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5542

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG. It’s time to bring dendritic cell therapy to type 1 diabetes. Diabetes (2014) 63:20–30.10.2337/db13-0886 PubMed DOI PMC

Dáňová K, Klapetková A, Kayserová J, Šedivá A, Špíšek R, Jelínková LP. NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget (2015) 6:14123–38.10.18632/oncotarget.4234 PubMed DOI PMC

Mansilla MJ, Sellès-Moreno C, Fàbregas-Puig S, Amoedo J, Navarro-Barriuso J, Teniente-Serra A, et al. Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis. CNS Neurosci Ther (2015) 21:222–30.10.1111/cns.12342 PubMed DOI PMC

Mansilla MJ, Contreras-Cardone R, Navarro-Barriuso J, Cools N, Berneman Z, Ramo-Tello C, et al. Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. J Neuroinflammation (2016) 13:113.10.1186/s12974-016-0584-9 PubMed DOI PMC

Popov I, Li M, Zheng X, San H, Zhang X, Ichim TE, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther (2006) 8:R141.10.1186/ar2031 PubMed DOI PMC

Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum (2010) 62:3656–65.10.1002/art.27756 PubMed DOI

Lord P, Spiering R, Aguillon JC, Anderson AE, Appel S, Benitez-Ribas D, et al. Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies. PeerJ (2016) 4:e2300.10.7717/peerj.2300 PubMed DOI PMC

Haase C, Ejrnaes M, Juedes AE, Wolfe T, Markholst H, von Herrath MG. Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood (2005) 106:4225–33.10.1182/blood-2005-03-0975 PubMed DOI PMC

Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature (1993) 366:69–72.10.1038/366069a0 PubMed DOI PMC

Iruretagoyena MI, Sepúlveda SE, Lezana JP, Hermoso M, Bronfman M, Gutiérrez MA, et al. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther (2006) 318:59–67.10.1124/jpet.106.103259 PubMed DOI

Healy LJ, Collins HL, Thompson SJ. Systemic administration of tolerogenic dendritic cells ameliorates murine inflammatory arthritis. Open Rheumatol J (2008) 2:71–80.10.2174/1874312900802010071 PubMed DOI PMC

Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG. A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice. Mol Ther (2010) 18:2112–20.10.1038/mt.2010.146 PubMed DOI PMC

Ma L, Qian S, Liang X, Wang L, Woodward JE, Giannoukakis N, et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-κB activity. Diabetes (2003) 52:1976–85.10.2337/diabetes.52.8.1976 PubMed DOI

Lo J, Peng RH, Barker T, Xia CQ, Clare-Salzler MJ. Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type 1 diabetes. Ann N Y Acad Sci (2006) 1079:153–6.10.1196/annals.1375.023 PubMed DOI

Gibson VB, Nikolic T, Pearce VQ, Demengeot J, Roep BO, Peakman M. Proinsulin multi-peptide immunotherapy induces antigen-specific regulatory T cells and limits autoimmunity in a humanized model. Clin Exp Immunol (2015) 182:251–60.10.1111/cei.12687 PubMed DOI PMC

Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al. 1,25-dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol (2014) 192:4210–20.10.4049/jimmunol.1302350 PubMed DOI

Nikolic T, Woittiez NJC, van der Slik A, Laban S, Joosten A, Gysemans C, et al. Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation. Genes Immun (2017) 18:176–83.10.1038/gene.2017.18 PubMed DOI

Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 69:2042–50.10.1136/ard.2009.126383 PubMed DOI PMC

García-González P, Morales R, Hoyos L, Maggi J, Campos J, Pesce B, et al. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J Transl Med (2013) 11:128.10.1186/1479-5876-11-128 PubMed DOI PMC

Dáňová K, Grohová A, Strnadová P, Funda DP, Šumník Z, Lebl J, et al. Tolerogenic dendritic cells from poorly compensated type 1 diabetes patients have decreased ability to induce stable antigen-specific T cell hyporesponsiveness and generation of suppressive regulatory T cells. J Immunol (2017) 198:729–40.10.4049/jimmunol.1600676 PubMed DOI

Sochorová K, Budinský V, Rozková D, Tobiasová Z, Dusilová-Silková S, Špíšek R, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol (2009) 133:69–77.10.1016/j.clim.2009.06.011 PubMed DOI

Naranjo-Gómez M, Raïch-Regué D, Oñate C, Grau-López L, Ramo-Tello C, Pujol-Borrell R, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med (2011) 9:89.10.1186/1479-5876-9-89 PubMed DOI PMC

Feili-Hariri M, Morel PA. Phenotypic and functional characteristics of BM-derived DC from NOD and non-diabetes-prone strains. Clin Immunol (2001) 98:133–42.10.1006/clim.2000.4959 PubMed DOI

Stojanovic I, Dimitrijevic M, Vives-Pi M, Mansilla MJ, Pujol-Autonell I, Rodríguez-Fernandez S, et al. Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis. Curr Pharm Des (2017) 23:2623–43.10.2174/1381612823666170214120708 PubMed DOI

Wells JW, Darling D, Farzaneh F, Galea-Lauri J. Influence of interleukin-4 on the phenotype and function of bone marrow-derived murine dendritic cells generated under serum-free conditions. Scand J Immunol (2005) 61:251–9.10.1111/j.1365-3083.2005.01556.x PubMed DOI

Feili-Hariri M, Falkner DH, Gambotto A, Papworth GD, Watkins SC, Robbins PD, et al. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther (2003) 14:13–23.10.1089/10430340360464679 PubMed DOI

Morel PA, Srinivas M, Turner MS, Fuschiotti P, Munshi R, Bahar I, et al. Gene expression analysis of dendritic cells that prevent diabetes in NOD mice: analysis of chemokines and costimulatory molecules. J Leukoc Biol (2011) 90:539–50.10.1189/jlb.0311126 PubMed DOI PMC

Smyth LA, Ratnasothy K, Moreau A, Alcock S, Sagoo P, Meader L, et al. Tolerogenic donor-derived dendritic cells risk sensitization in vivo owing to processing and presentation by recipient APCs. J Immunol (2013) 190:4848–60.10.4049/jimmunol.1200870 PubMed DOI PMC

Price JD, Beauchamp NM, Rahir G, Zhao Y, Rieger CC, Lau-Kilby AW, et al. CD8+ dendritic cell-mediated tolerance of autoreactive CD4+ T cells is deficient in NOD mice and can be corrected by blocking CD40L. J Leukoc Biol (2014) 95:325–36.10.1189/jlb.0113013 PubMed DOI PMC

Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med (2002) 196:369–77.10.1084/jem.20011353 PubMed DOI PMC

Höglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med (1999) 189:331–9.10.1084/jem.189.2.331 PubMed DOI PMC

Katz JD, Ondr JK, Opoka RJ, Garcia Z, Janssen EM. Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol (2010) 185:1999–2003.10.4049/jimmunol.1001398 PubMed DOI PMC

Jang MH, Sougawa N, Tanaka T, Hirata T, Hiroi T, Tohya K, et al. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol (2006) 176:803–10.10.4049/jimmunol.176.2.803 PubMed DOI

Roe MM, Swain S, Sebrell TA, Sewell MA, Collins MM, Perrino BA, et al. Differential regulation of CD103 (αE integrin) expression in human dendritic cells by retinoic acid and toll-like receptor ligands. J Leukoc Biol (2017) 101:1169–80.10.1189/jlb.1MA0316-131R PubMed DOI PMC

Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 183:4895–903.10.4049/jimmunol.0901459 PubMed DOI PMC

Gale EA. A missing link in the hygiene hypothesis? Diabetologia (2002) 45:588–94.10.1007/s00125-002-0801-1 PubMed DOI

Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol Today (1993) 14:426–30.10.1016/0167-5699(93)90244-F PubMed DOI

Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications

Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?